Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.41 |
| ▸ | PARL | Q9H300 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653363 | 0.82 | CRHBP (0.39) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL5654480 | 0.82 | CRHBP (0.39) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL30912424 | 0.81 | KMT2A (0.46) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL30912496 | 0.81 | KMT2A (0.46) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL9891746 | 0.79 | CNR2 (0.45) | GFERKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL9891736 | 0.79 | ALDH1A1 (0.41) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL9891735 | 0.78 | CNR2 (0.48) | — | |
| SCHEMBL27959325 | 0.77 | CRHBP (0.43) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL9893017 | 0.77 | KMT2A (0.46) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL9891747 | 0.77 | CNR2 (0.47) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CRHBP 113/4885GFER 3344/4885CRHR2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.